A growing number of South Dakotans are shedding pounds thanks to GLP-1 medications, but now they’re hitting a roadblock.

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

FROM sulphur burps to diarrhoea and nausea, there are many widely known Ozempic side effects – but there’s also a whole host of nasty long-term issues experts are only just uncovering.

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

A new study suggests GLP-1 class weight-loss drugs may lower cancer risk in people with diabetes. It looked at 170,000 patient records, and found there's a slightly lower risk of obesity-related ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Weight loss jabs combined with lifestyle choices can be a gamechanger for those stuck in the cycle of yo-yo-dieting.

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.